Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:48:50.621Z.
Consensus retrieved: 2026-10-06T15:40:21.454Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:48:50.621Z.
Quote observation: 2026-10-06T16:45:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 98ff119f91c2c633a3a1f1b2756f2fc2c642959d743c2bc4f338d66319263a00
Forward PE Ratio (N/A) = Dated Quote Price ($22.13) / Consensus Forward EPS ($-3.89)
FORWARD PE RATIO
N/A
uniQure N.V.
Market Cap
$1.54B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| uniQure N.V. (QURE) | $1.54B | N/A |
| Nutex Health, Inc. (NUTX)vs › | $1.54B | 8.04 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.65 |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.55B | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.50B | 10.58 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 50.20 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 15.54 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $22.13, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.89 | $-4.23 – $-3.62 | 8 | n/m |
| 2027-12-31 | $-3.08 | $-3.36 – $-2.69 | 8 | n/m |
| 2028-12-31 | $-1.38 | $-4.95 – $3.68 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
